Pathobiology of pulmonary hypertension: The role of platelets and thrombosis

Clinics in Chest Medicine

Volumn 22, Issue 3, 2001, Pages 451-458

  Herve, Philippe ^a   Humbert, Marc ^a   Sitbon, Olivier ^a   Parent, Florence ^a   Nunes, Hilario ^a   Legal, Catherine ^a   Garcia, Gilles ^a   Simonneau, Gerald ^a  

^a UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBIN; BLOOD CLOTTING FACTOR 5; PHOSPHOLIPID; PROTEIN C; PROTEIN S; PROTHROMBIN; SEROTONIN; VASCULOTROPIN;

ANTICOAGULATION; HISTOPATHOLOGY; HUMAN; LUNG ENDOTHELIUM; MUTATION; PATHOGENESIS; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; RISK ASSESSMENT; THROMBOCYTE ACTIVATION; THROMBOCYTE FUNCTION; THROMBOCYTOPENIA; THROMBOSIS;

EID: 0034803631     PISSN: 02725231     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0272-5231(05)70283-5     Document Type: Article

References (51)

1. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International primary pulmonary hypertension study group
2. Pulmonary hypertension and right heart failure in patients with Β-thalassemia intermedia
3. Paradoxical constriction to platelets by arteries from rats with pulmonary hypertension
4. Evaluation of patients with suspected chronic thromboembolic pulmonary hypertension
5. Lung perfusion scans and hemodynamics in acute and chronic pulmonary embolism
6. Continuous infusion of prostacyclin decreases plasma levels of t-PA and PAI-1 in primary pulmonary hypertension
7. Plasma levels of thrombomodulin in pulmonary hypertension
8. The role of thrombosis in severe pulmonary hypertension
9. Characterization of von Willebrand factor in primary pulmonary hypertension
10. Pulmonary hypertension and cor pulmonale in the sickle hemoglobinopathies
11. Obesity drugs and the heart
12. Angioscopic video-assisted pulmonary endarterectomy for post-embolic pulmonary hypertension
13. Imbalance between platelet VEGF and PDGF in pulmonary hypertension, effect of prostacyclin therapy
14. A new role for an old molecule: Serotonin as a mitogen
15. Progressive splenomegaly after epoprostenol therapy in porto-pulmonary hypertension
16. The effect of anticoagulant therapy in primary and anorectic drug-induced pulmonary hypertension
17. Continuous infusion of prostacyclin normalizes plasma markers of endothelial cell injury and platelet aggregation in primary pulmonary hypertension
18. Primary pulmonary hypertension: Natural history and the importance of thrombosis
19. Pulmonary hypertension in patients with myelofibrosis secondary to myeloproliferative diseases
20. Primary pulmonary hypertension in a patient with a familial platelet storage pool disease: Role of serotonin
21. Increased plasma serotonin in primary pulmonary hypertension
22. Plasma coagulation profiles in patients with severe primary pulmonary hypertension
23. Pulmonary hypertension after splenectomy?
24. Elevated plasma serotonin levels in pulmonary arterial hypertension are not related to platelet activation
25. Short-term and long-term epoprostenol (prostacyclin) therapy in pulmonary hypertension secondary to connective tissue diseases: Results of a pilot study
26. A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation
27. High prevalence of antiphospholipid antibodies in precapillary pulmonary hypertension
28. No increased prevalence of the factor V Leiden mutation in chronic major vessel thromboembolic pulmonary hypertension
29. Circulating platelet aggregates indicative of in vivo platelet activation in pulmonary hypertension
30. Heterogeneity of pathologic lesions in familial primary pulmonary hypertension
31. 5-Hydroxy-tryptamine and the pulmonary circulation: Receptors, transporters and relevance to pulmonary arterial hypertension
32. Phentermine and other monoamine-oxidase inhibitors may increase plasma serotonin when given with fenfluramines
33. Primary pulmonary hypertension, tissue plasminogen activator anti-bodies and HLA-DQ7
34. Chronic major-vessel thromboembolic pulmonary hypertension
35. Do Patients with primary pulmonary hypertension develop extensive central thrombi?
36. Endogenous fibrinolytic system in chronic large-vessel thrombo-embolic pulmonary hypertension
37. The pathology of primary pulmonary hypertension
38. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension
39. Pulmonary hypertension associated with long-standing thrombocytosis
40. Microangiopathic hemolytic anemia and thrombocytopenia in primary pulmonary hypertension
41. Pulmonary hypertension in sickle cell disease
42. Microangiopathic hemolytic anemia and thrombocytopenia in a child with atrial septal defect and pulmonary hypertension
43. Pulmonary hypertension and sickle hemoglobinopathy
44. Spherocytosis and pulmonary hypertension coincidental occurrence or causal relationship?
45. Improvement of von Willebrand factor proteolysis after prostacyclin infusion in severe pulmonary hypertension
46. Pathology of pulmonary thrombo-embolism
47. Thrombotic lesions in primary plexogenic arteriopathy. Similar pathogenesis or complication?
48. Coagulation and fibrinolytic profiles in patients with severe pulmonary hypertension
49. Thrombotic risk factors in pulmonary hypertension
50. Absence of hyperhomocysteinemia in 10 patients with primary pulmonary hypertension